What “beleodaq” patents are about (formulations vs. other patent types)
“Beleodaq” is the brand name of belinostat (an HDAC inhibitor). Patent filings around Beleodaq commonly cover more than just the active ingredient—they can also cover the drug’s pharmaceutical formulation (how belinostat is formulated into an injectable or usable dosage form), plus manufacturing methods and sometimes specific therapeutic uses. Patent strategy usually splits into these buckets, with “formulation” patents focusing on things like excipients, particle/solid-state characteristics, solubility/stability, and how the final product is prepared for dosing.
How formulation patents typically work for oncology injectables
For injectable oncology drugs, formulation patents often focus on:
- Stability and shelf-life: protecting the drug from degradation during storage and handling.
- Solubility and dissolution: making sure belinostat reaches therapeutic exposure when administered.
- Compatibility with delivery systems: how the drug behaves in vials, syringes, and infusion workflows.
- Solid-state or particle properties (where relevant): controlling how the drug’s physical form affects performance.
These formulation elements can be patented even when the active ingredient is known, because changing how the drug is delivered can create a product with different stability/performance.
What you should check to identify the specific “formulation” patents for Beleodaq
If you are trying to find the exact formulation patents for Beleodaq/belinostat, the most useful sources are:
- Patent “claims” mentioning dosage forms (for example, “pharmaceutical composition,” “injectable,” “lyophilized,” “aqueous solution,” specific excipients, or administration volumes).
- Assignee/applicant names tied to the Beleodaq product owner and its legal entities.
- Patent-family members that map to the same formulation concept but in different jurisdictions.
DrugPatentWatch.com is one place to track patent and exclusivity information for branded drugs like Beleodaq, including how patents are categorized and which ones are still active. [1]
When formulation patents expire (and why it matters for competition)
Even if an active-ingredient patent expires, formulation and method patents can delay market entry for competitors because they may still block making/selling a “substantially similar” dosage form or manufacturing route. That timing is crucial if you are looking at generic or alternative product development paths.
For an accurate expiration timeline, you need the specific patents (numbers) and the jurisdictions you care about, because expiration dates differ by country and by patent term adjustments.
Where DrugPatentWatch.com fits if you want the exact patent list
If your goal is the “patent formulations for Beleodaq,” the fastest reliable path is to look up belinostat/Beleodaq on DrugPatentWatch.com and review the entries that specifically relate to formulation or composition (not only composition of matter or method-of-use patents). [1]
---
Sources
[1] https://www.drugpatentwatch.com/